 | Up a level |
Journal Article
Borchmann, Peter, Goergen, Helen, Kobe, Carsten, Lohri, Andreas, Greil, Richard, Eichenauer, Dennis A., Zijlstra, Josee M., Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Huttmann, Andreas 
ORCID: 0000-0003-2230-3873, Dierlamm, Judith, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S., Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kuhnhardt, Dagmar, Ostermann, Helmut, Schmitz, Norbert, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Kuhnert, Georg, Diehl, Volker, Dietlein, Markus and Engert, Andreas
(2017).
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Lancet, 390 (10114).
S. 2790 - 2803.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
Borchmann, Peter, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Huettmann, Andreas, Keil, Felix, Dierlamm, Judith, Haenel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josee M., Fossa, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Kamper, Peter, Molin, Daniel, Kreissl, Stefanie, Fuchs, Michael, Schneider, Gundolf, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans, Baues, Christian, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, Diehl, Volker and Engert, Andreas (2022). Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Jacob, Anne Sophie, Kaul, Helen, Fuchs, Michael, Gillessen, Sarah, Kreissl, Stefanie, Pluetschow, Annette, Momotow, Jesko, Schaub, Valdete, Huettmann, Andreas, Haenel, Mathias, Zimmermann, Andreas, Dierlamm, Judith, Meissner, Julia, Mathas, Stephan, Martin, Sonja, Engert, Andreas, Hallek, Michael ORCID: 0000-0002-7425-4455, Borchmann, Peter and Lehmann, Clara
(2022).
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Infection, 50 (4).
S. 925 - 933.
HEIDELBERG:
SPRINGER HEIDELBERG.
ISSN 1439-0973
Pfreundschuh, Michael, Murawski, Niels, Ziepert, Marita, Altmann, Bettina, Dreyling, Martin H., Borchmann, Peter, Luminari, Stefano, Witzens-Harig, Mathias, Dierlamm, Judith, Haenel, Mathias, Truemper, Lorenz, Metzner, Bernd, Lengfelder, Eva, Keller, Ulrich B., Ruebe, Christian, Berdel, Christian, Schmitz, Norbert, Held, Gerhard and Poeschel, Viola (2018). Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra ORCID: 0000-0003-3052-7463, Brown, Peter de Nully ORCID: 0000-0002-6522-4086, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf ORCID: 0000-0001-7565-7160, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus and Pfreundschuh, Michael
(2019).
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet, 394 (10216).
S. 2271 - 2282.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X